Alvotech stock (LU2557688560): Partner Fuji Pharma reports valuation drop

Alvotech, a clinical-stage biosimilar developer, drew attention after partner Fuji Pharmaceutical Industries reported a securities evaluation loss on its stake in the company. Fuji disclosed the writedown in its financial summary published on May 12, 2026, attributing it to a decrease in Alvotech's stock valuation amid biosimilar business challenges. The stock traded at $14.25 USD on May 13, 2026 on Nasdaq, according to Stock Analysis as of 05/13/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Alvotech: core business model

Alvotech develops biosimilar medicines targeting blockbuster biologics, with a pipeline focused on ophthalmology, immunology, and oncology. The company licenses products to global partners like Teva Pharmaceuticals, STADA, and Fuji Pharma for commercialization. Its lead candidate AVT02, a Humira biosimilar, received FDA approval, enabling US market entry via partners. Alvotech retains no commercial infrastructure, emphasizing R&D and manufacturing in Iceland.

Revenue stems from upfront payments, milestones, and royalties. As of its latest filings, Alvotech reported growing partnership income, with key deals providing non-dilutive funding. The model appeals to US investors seeking exposure to the $100B+ global biosimilars market projected through 2030, per EvaluatePharma as of 2025.

Main revenue and product drivers for Alvotech

Pipeline progress drives value, with AVT04 ( Stelara biosimilar) in late-stage trials and AVT06 (Soliris) advancing. Partnerships with Teva, a major US player, position Alvotech for significant royalties upon launches. In Q4 2025 results published March 2026, milestone revenues rose 25% YoY to $15M for the period ending Dec 31, 2025, per investor filings.

Fuji Pharma's May 12, 2026 update highlights valuation pressures but underscores ongoing collaboration on Japan commercialization. US relevance grows as biosimilars erode biologics pricing, benefiting payers and investors tracking Nasdaq biotech.

Industry trends and competitive position

Biosimilars adoption accelerates in the US, with Humira copies capturing 90% market share by 2026. Alvotech competes with Samsung Bioepis, Sandoz, and Celltrion but differentiates via complex molecules like eye injectables. Its Iceland facility supports high-quality production, key for FDA approvals.

Why Alvotech matters for US investors

Nasdaq-listed Alvotech offers pure-play biosimilars exposure amid patent cliffs for AbbVie and Regeneron drugs. Partnerships with US giant Teva link it directly to American healthcare spending, which drives 45% of global pharma revenues.

Conclusion

Alvotech navigates partner-reported valuation challenges amid a robust biosimilars pipeline. With FDA approvals and Teva collaborations, the company eyes commercialization milestones. US investors monitor Nasdaq trading for updates on trial data and launches. Developments remain key in the competitive biotech landscape.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.